GE HealthCare recalled a dual-head nuclear medicine gamma camera on September 12, 2025, after identifying a risk of detector falls. One unit is affected, posing a high risk of life-threatening injury. Users must stop using the device immediately and follow manufacturer instructions.
GE HealthCare has become aware that certain Nuclear Medicine systems that are past the End of Guaranteed Service could have been transported or relocated without adequate detector support. This could result in excessive stress being applied to the detector mounting mechanisms, compromising their integrity. If this occurs, it can potentially result in a detector fall and lead to life-threatening bodily injury.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact GE MEDICAL SYSTEMS ISRAEL, FUNCTIONAL IMAGING or your healthcare provider for instructions. Notification method: Letter
The recall affects the Optima NX dual-head nuclear medicine gamma camera. It was distributed worldwide and includes all serial numbers in distribution.
The camera may have been relocated without adequate detector support. This can stress the detector mounting mechanisms, risking a fall that could cause serious injuries.
Currently, no specific incidents have been reported. The potential for life-threatening injury exists if the detector falls.
Immediately stop using the device. Contact GE Medical Systems Israel for further instructions regarding the recall.
For more information, visit the GE HealthCare website or contact your healthcare provider. Recall notifications are sent via letter.
Get notified about recalls in categories you care about.
Bristol-Myers Squibb recalled 12,778 vials of Opdualag injection on October 21, 2025. The recall stems from a lack of assurance of sterility. The affected products were distributed nationwide in the United States.
Major Pharmaceuticals recalled Gabapentin Capsules, USP, 100 mg, on October 10, 2025, due to failed impurities specifications. The recall affects several lot numbers distributed nationwide. Consumers must stop using the affected capsules immediately.
Lannett Company, Inc. recalled 46,848 bottles of Niacin Extended-release Tablets on October 10, 2025. The recall follows reports of failed dissolution specifications, which could affect medication effectiveness. Consumers should stop using the product immediately and consult healthcare providers for guidance.